Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Isis Pharmacueticals

Biogen Idec building

FDA approves Biogen’s Spinraza for spinal muscular atrophy

Analysts predict blockbuster sales as drug is priced at $750,000 for first year of treatment

Roche Basel Switzerland

Roche’s haemophilia A drug hits targets in registration trial

Emicizumab from Japanese affiliate Chugai cleared a phase III trial

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

Roche Basel Switzerland

Genentech names Anderson new CEO as Ian Clark retires

Leadership changes come as the Roche subsidiary faces increasing biologics competition

- PMLiVE

Intercept gets EU nod for rare liver disease therapy

Ocaliva approved as a combination treatment for primary biliary cholangitis

- PMLiVE

Novartis’ AMD drug pegpleranib fails phase III programme

Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit

- PMLiVE

Pfizer’s SMO inhibitor boosts survival in blood cancer trial

Glasdegib first to show benefit in patients with AML or MDS

- PMLiVE

Shire to focus rare disease R&D with new US facility

Cambridge, Massachusetts hub to drive firm’s push to become leading rare disease specialist

Roche's Perjeta pertuzumab

NICE backs Roche’s Perjeta for routine NHS use

Set to become first new breast cancer drug in nine years after discount agreed

- PMLiVE

Boehringer says Avastin biosimilar on track as Phase III gets underway

Clinical data suggests candidate has same biologic profile as Roche’s cancer drug

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

- PMLiVE

Orphan drugs: Leading the way in patient-centricity

What lessons about optimal patient engagement can big pharma learn from those operating in rare disease?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links